Dogwood reports Q2 2026 results as Halneuron Phase 2b nears fall readout
Dogwood Therapeutics said its 217-patient Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain remains on track for top-line data in fall 2026, with cash of $9.6 million.
SEC filing